Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VSJ-110 for Allergic Conjunctivitis
Go back to Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VSJ-110 for Allergic Conjunctivitis| Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) | Delayed: 5.16 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.16 | 52 Week High | $18.00 | |||
| Open | $5.19 | 52 Week Low | $6.91 | |||
| Day High | $5.21 | P/E | N/A | |||
| Day Low | $5.10 | EPS | $-0.67 | |||
| Volume | 127,708 | |||||
